14 September 2022: Clinical Research
C-Reactive Protein/Albumin Ratio at Diagnosis of Pediatric Inflammatory Bowel Disease: A Retrospective Multi-Center Study
Aleksandra Glapa-Nowak 1ABCDEF , Mariusz Szczepanik 1ABE , Aleksandra Banaszkiewicz 2BE , Jarosław Kwiecień 3BE , Anna Szaflarska-Popławska 4BE , Urszula Grzybowska-Chlebowczyk 5BE , Marcin Osiecki 6BE , Jarosław Kierkuś 6BE , Marcin Dziekiewicz 2BE , Jarosław Walkowiak 1ACDEFG*DOI: 10.12659/MSM.937842
Med Sci Monit 2022; 28:e937842
Table 3 Significant correlations with CRP/albumin ratio at diagnosis in children with Crohn’s disease.
| Parameter | n | Median (IQR) | rho | p value |
|---|---|---|---|---|
| Age at first immunosuppressive treatment [years] | 143 | 13.1 (10.8–15.2) | 0.20 | 0.018 |
| Time-to-first biological treatment [months] | 86 | 12.1 (4.7–26.0) | −0.37 | |
| Time-to-first surgery [months] | 19 | 11.5 (0.0–29.1) | 0.56 | 0.012 |
| Days of hospitalization for relapse/year | 109 | 4.4 (1.4–7.2) | 0.26 | 0.007 |
| Severe relapses from diagnosis/year | 106 | 0.2 (0.0–0.5) | 0.31 | 0.001 |
| PCDAI at diagnosis | 172 | 32 (23–48) | 0.38 | 0.002 |
| PCDAI at worst flare | 150 | 39 (30–53) | 0.19 | 0.023 |
| IQR – interquartile range; PCDAI – Pediatric Crohn’s Disease Activity Index. | ||||